dc.contributor
[Lopes de Faria JM, Duarte DA, Dátilo MN, Pasqualetto FC] Renal Pathophysiology Laboratory, Investigation on Diabetes Complications, Faculty of Medical Sciences, State University of Campinas (UNICAMP), Campinas, Brazil. [Simó R, García-Ramirez M] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Lopes de Faria, Jacqueline M.
dc.contributor.author
Duarte, Diego A.
dc.contributor.author
García Ramírez, Marta
dc.contributor.author
Dátilo, Marcella N.
dc.contributor.author
Pasqualetto, Francieli C.
dc.contributor.author
Simó Canonge, Rafael
dc.date.accessioned
2025-10-24T08:57:25Z
dc.date.available
2025-10-24T08:57:25Z
dc.date.issued
2020-07-02T11:25:50Z
dc.date.issued
2020-07-02T11:25:50Z
dc.date.issued
2019-09-03
dc.identifier
Lopes de Faria JM, Duarte DA, Simó R, García-Ramirez M, Dátilo MN, Pasqualetto FC, et al. δ Opioid receptor agonism preserves the retinal pigmented epithelial cell tight junctions and ameliorates the retinopathy in experimental diabetes. Investig Ophthalmol Vis Sci. 2019 Sep 3;60(12):3842–53.
dc.identifier
https://hdl.handle.net/11351/5057
dc.identifier
10.1167/iovs.19-26761
dc.identifier
000486495800018
dc.identifier.uri
http://hdl.handle.net/11351/5057
dc.description.abstract
Diabetic retinopathy; Diabetes; Delta opioid receptor
dc.description.abstract
Retinopatía diabética; Diabetes; Receptor opioide delta
dc.description.abstract
Retinopatia diabètica; Diabetis; Receptor opioide delta
dc.description.abstract
Purpose: Outer blood retinal barrier breakdown is a neglected feature of diabetic retinopathy (DR). We demonstrated that the agonism of the δ opioid receptor (DOR) by epicatechin preserves the tight junction proteins in ARPE-19 cells under diabetic conditions. Presently, we aimed to evaluate the possible role of the DOR on the maintenance of tight junction of RPE layer and on the early markers of experimental DR. Methods: DR markers and external retinal tight junction proteins were evaluated in CL57B diabetic mice submitted to intravitreous injection of short hairpin RNA (shRNA)-DOR (108 transducing units [TU]/mL) treated or not with DOR agonist (0.05 g/animal/d of epicatechin in drinking water) for 16 weeks. The presence of DOR in human retina from postmortem eyes from diabetic and nondiabetic donors were also performed. Results: DOR is present in RPE layer and in neuro retina. The treatment with DOR agonist prevented the upregulation of the early markers of retinopathy (glial fibrillary acidic protein, VEGF) and the downregulation of pigment epithelium-derived factor, occludin, claudin-1, and zonula occludens-1 tight junction expressions. The silencing of DOR in retina of diabetic mice partially abolished the protective effects of epicatechin. In human retina specimens, DOR is present throughout the retina, similarly in nondiabetic and diabetic donors. Conclusions: This set of experiments strongly indicates that the DOR agonism preserves RPE tight junctions and reduces the early markers of retinopathy in model of diabetes. These novel findings designate DOR as a potential therapeutic tool to treat DR with preservation of the RPE tight junction proteins.
dc.format
application/pdf
dc.format
application/pdf
dc.format
application/pdf
dc.publisher
Association for Research in Vision and Ophthalmology
dc.relation
Investigate Ophthalmology & Visual Science;60(12)
dc.relation
https://iovs.arvojournals.org/article.aspx?articleid=2751563
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Neurotransmissors - Receptors
dc.subject
Retinopatia diabètica
dc.subject
Retina - Vasos sanguinis
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, G-Protein-Coupled::Receptors, Opioid::Receptors, Opioid, delta
dc.subject
DISEASES::Endocrine System Diseases::Diabetes Mellitus::Diabetes Complications::Diabetic Angiopathies::Diabetic Retinopathy
dc.subject
ANATOMY::Cardiovascular System::Blood-Retinal Barrier
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores acoplados a proteínas G::receptores opioides::receptores opiodes delta
dc.subject
ENFERMEDADES::enfermedades del sistema endocrino::diabetes mellitus::complicaciones de la diabetes::angiopatías diabéticas::retinopatía diabética
dc.subject
ANATOMÍA::sistema cardiovascular::barrera hematorretinal
dc.title
δ opioid receptor agonism preserves the retinal pigmented epithelial cell tight junctions and ameliorates the retinopathy in experimental diabetes
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
